Discovery and development of surotomycin for the treatment of Clostridium difficile

Journal of Industrial Microbiology and Biotechnology

Volumn 43, Issue 2-3, 2016, Pages 195-204

  Knight Connoni, Victoria ^a   Mascio, Carmela ^a   Chesnel, Laurent ^a,b   Silverman, Jared ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Clostridium difficile; Diarrhea; Gastrointestinal; Surotomycin; Vancomycin

Indexed keywords

SUROTOMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE;

AEROBIC FERMENTATION; ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CELL MEMBRANE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLOSTRIDIUM DIFFICILE INFECTION; CONCENTRATION RESPONSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; EVIDENCE BASED PRACTICE; GASTROINTESTINAL TRACT; HUMAN; IN VITRO STUDY; INCIDENCE; INTESTINE FLORA; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; STREPTOMYCES; SURVIVAL RATE; TREATMENT RESPONSE; ANIMAL; BIOAVAILABILITY; CLOSTRIDIUM INFECTIONS; CYTOLOGY; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS, PHASE II AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; GASTROINTESTINAL MICROBIOME; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC;

EID: 84958125272     PISSN: 13675435     EISSN: 14765535     Source Type: Journal    
DOI: 10.1007/s10295-015-1714-6     Document Type: Review

References (38)

1. Adams HM, Li X, Mascio C, Chesnel L, Palmer KL (2015) Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species. Antimicrob Agents Chemother 59:4139–4147. doi:10.1128/AAC.00526-15
2. Alam MZ, Wu X, Mascio C, Chesnel L, Hurdle JG (2015) Mode of action and bactericidal properties of surotomycin against growing and non-growing Clostridium difficile. Antimicrob Agents Chemother 59:5165–5170. doi:10.1128/AAC.01087-15
3. Boeck LD, Fukuda DS, Abbott BJ, Debono M (1988) Deacylation of A21978C, an acidic lipopeptide antibiotic complex, by Actinoplanes utahensis. J Antibiot (Tokyo) 41:1085–1092
4. Bouillaut L, McBride S, Sorg JA, Schmidt DJ, Suarez JM, Tzipori S, Mascio C, Chesnel L, Sonenshein AL (2015) Effects of surotomycin on Clostridium difficile viability and toxin production in vitro. Antimicrob Agents Chemother 59:4199–4205. doi:10.1128/AAC.00275-15
5. Cannon K, Byrne B, Happe JS, Louie T (2012) Enteric microbiome profiles during a phase 2 clinical trial of CB-183,315 or vancomycin for treatment of Clostridium difficile infection. Presented at 22nd European congress of clinical microbiology and infectious diseases (ECCMID), London, UK, March 31–April 3, 2012. Poster P 2250
6. Chandorkar G, Zhan Q, Donovan J, Rege S, Patino H (2013) Pharmacokinetics of surotomycin from a phase 1 multiple ascending dose study in healthy volunteers. Presented at IDWeek 2013, San Francisco, CA, October 2–6, 2013. Poster 719
7. Chilton CH, Crowther GS, Todhunter SL, Nicholson S, Freeman J, Chesnel L, Wilcox MH (2014) Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother 69:2426–2433. doi:10.1093/jac/dku141
8. Citron DM, Tyrrell KL, Goldstein EJC (2010) Impact of CB-183,315, a novel lipopeptide, on fecal flora of 30 subjects in a phase I clinical trial. Presented at Interscience conference on antimicrobial agents and chemotherapy, Boston, MA, September 12–15, 2010. Oral presentation
9. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ (2012) In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob Agents Chemother 56:1613–1615. doi:10.1128/AAC.05655-11
10. CLSI (2009) Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard. CLSI document M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA
11. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31:431–455. doi:10.1086/651706
12. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, Group OPTCS (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281–289. doi:10.1016/S1473-3099(11)70374-7
13. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE, for the Study 003/004 Teams (2012) Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 55(Suppl 2):S93–103. doi:10.1093/cid/cis499
14. Cubist Pharmaceuticals Study of CB-183,315 in patients with Clostridium difficile associated diarrhea. http://clinicaltrials.gov/ct2/show/NCT01597505?term=CB-183%2C315&rank=2&submit_fld_opt. Accessed 9 Oct 2015
15. Cubist Pharmaceuticals A Study of CB-183,315 in patients with Clostridium difficile associated diarrhea. http://clinicaltrials.gov/ct2/show/NCT01598311?term=CB-183%2C315&rank=3&submit_fld_opt. Accessed 9 Oct 2015
16. D’Costa VM, Mukhtar TA, Patel T, Koteva K, Waglechner N, Hughes DW, Wright GD, De Pascale G (2012) Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms. Antimicrob Agents Chemother 56:757–764. doi:10.1128/AAC.05441-11
17. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD (2003) Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 47:1318–1323
18. Eisenstein BI, Oleson FB Jr, Baltz RH (2010) Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 50(Suppl 1):S10–S15. doi:10.1086/647938
19. Francis MB, Allen CA, Sorg JA (2015) Spore cortex hydrolysis precedes DPA release during Clostridium difficile spore germination. J Bacteriol 197:2276–2283. doi:10.1128/JB.02575-14
20. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ (2012) Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92:453–488. doi:10.1016/j.tube.2012.07.003
21. Goudarzi M, Seyedjavadi SS, Goudarzi H, Mehdizadeh Aghdam E, Nazeri S (2014) Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Scientifica (Cairo) 2014:916826. doi:10.1155/2014/916826
22. Hurdle JG, O’Neill AJ, Chopra I, Lee RE (2011) Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9:62–75. doi:10.1038/nrmicro2474
23. Jarrad AM, Karoli T, Blaskovich MA, Lyras D, Cooper MA (2015) Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J Med Chem 58:5164–5185. doi:10.1021/jm5016846
24. Johnson S (2009) Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 58:403–410. doi:10.1016/j.jinf.2009.03.010
25. Lanis JM, Heinlen LD, James JA, Ballard JD (2013) Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog 9:e1003523. doi:10.1371/journal.ppat.1003523
26. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC (2015) Burden of Clostridium difficile infection in the United States. N Engl J Med 372:825–834. doi:10.1056/NEJMoa1408913
27. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, for the OPT-80-003 Clinical Study Group (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422–431. doi:10.1056/NEJMoa0910812
28. Mascio CT, Chesnel L, Thorne G, Silverman JA (2014) Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 58:3976–3982. doi:10.1128/AAC.00124-14
29. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA (2012) In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 56:5023–5030. doi:10.1128/AAC.00057-12
30. McFarland LV (2005) Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 54:101–111
31. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G (2010) Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192:4904–4911. doi:10.1128/JB.00445-10
32. Mortin LI, Van Praagh ADG, Zhang S, Arya A, Chuong L, Kang C, Zhang X, Li T (2010) Efficacy of CB-183,315, a novel lipopeptide antibiotic, in a hamster model of Clostridium difficile infection (CDI). Presented at Interscience conference on antimicrobial agents and chemotherapy, Boston, MA, September 12–15, 2010. Poster B-707
33. Patino H, Stevens C, Louie T, Bernardo P, Friedland I (2011) Efficacy and safety of the lipopeptide CB-183,315 for the treatment of C. difficile infection. Presented at Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17–20, 2011. Poster 230
34. Snydman DR, Jacobus NV, McDermott LA (2012) Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob Agents Chemother 56:3448–3452. doi:10.1128/AAC.06257-11
35. Steele SR, McCormick J, Melton GB, Paquette I, Rivadeneira DE, Stewart D, Buie WD, Rafferty J (2015) Practice parameters for the management of Clostridium difficile infection. Dis Colon Rectum 58:10–24. doi:10.1097/DCR.0000000000000289
36. Sunenshine RH, McDonald LC (2006) Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73:187–197
37. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478–498; quiz 499. doi:10.1038/ajg.2013.4
38. Yin N, Li J, He Y, Herradura PS, Pearson A, Mesleh MF, Mascio CT, Howland K, Steenbergen J, Thorne GM, Citron D, Van Praagh AD, Mortin LI, Keith D, Silverman J, Metcalf C (2015) Structure-activity relationship studies of a series of semi-synthetic lipopeptides leading to the discovery of surotomycin, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficile-associated diarrhea. J Med Chem 58:5137–5142. doi:10.1021/acs.jmedchem.5b00366